ESMO 2025: Aktuelle Studien zum Endometriumkarzinom sowie Zervixkarzinom & Vulvakrebs

In this video, patient representative and chairwoman of the German Association for Gynecological Cancers (Gynecological Cancers Deutschland e. V.), Kirsten Hahn, and Prof. Barbara Schmalfeldt from the University Medical Center Hamburg-Eppendorf discuss current studies on endometrial cancer, cervical cancer, and vulvar cancer. For example, the KEYNOTE-755 and LEAP-001 studies aimed to examine the efficacy and tolerability of the combination of the drugs lenvatinib and pembrolizumab compared to conventional chemotherapy. The analysis is based on data from two large studies and focuses on patients who had previously undergone chemotherapy. This coverage of the European Society for Medical Oncology (ESMO) Congress is provided by Patients Today (https://patientstoday.de/) and is made possible with the kind support of Lilly, SpringWorks Therapeutics, AstraZeneca, Daiichi-Sankyo, and Gilead.